Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual Meeting
Akouos, Inc. (NASDAQ: AKUS) announced the presentation of new nonclinical data at the American Society of Gene and Cell Therapy 24th Annual Meeting from May 11-14, 2021. The data will support the clinical development of two gene therapies: AK-OTOF for otoferlin gene-mediated hearing loss and AK-antiVEGF for vestibular schwannoma treatment. Presentations will occur on May 11, highlighting in vitro and in vivo analyses, auditory function recovery in mouse models, and tolerability of delivery approaches in non-human primates.
- Presentation of new nonclinical data supports future clinical development.
- AK-OTOF shows potential for treatment of otoferlin gene-mediated hearing loss.
- AK-antiVEGF demonstrates tolerability in non-human primates.
- None.
BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American Society of Gene and Cell Therapy 24th Annual Meeting, which is being held virtually from May 11 to 14, 2021.
Three digital presentations will highlight nonclinical data that support future clinical development of AK-OTOF, a gene therapy intended for the treatment of otoferlin gene (OTOF)-mediated hearing loss, and AK-antiVEGF, a gene therapy intended for the treatment of vestibular schwannoma. These digital presentations will occur on Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. EDT.
Details are as follows:
Digital Presentation Title: In Vitro and In Vivo Analyses of Dual Vector Otoferlin Expression to Support the Clinical Development of AK-OTOF (AAVAnc80-hOTOF Vector)
Presenting Author: Eva Andres-Mateos
Session Title: AAV Vectors - Preclinical and Proof-of-Concept Studies
Abstract Number: 355
Digital Presentation Title: Durable Recovery of Auditory Function Following Intracochlear Delivery of AK-OTOF (AAVAnc80-hOTOF Vector) in a Translationally Relevant Mouse Model of Otoferlin Gene (OTOF)-Mediated Hearing Loss
Presenting Author: Ann Hickox
Session Title: Neurologic Diseases
Abstract Number: 569
Digital Presentation Title: Demonstration of Tolerability of a Novel Delivery Approach and Secreted Protein Expression Following Intracochlear Delivery of AK-antiVEGF (AAVAnc80-antiVEGF Vector) in Non-Human Primates
Presenting Author: John Connelly
Session Title: AAV Vectors - Preclinical and Proof-of-Concept Studies
Abstract Number: 358
About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.
Contacts
Media:
Katie Engleman, 1AB
katie@1abmedia.com
Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com
FAQ
What is Akouos presenting at the American Society of Gene and Cell Therapy Annual Meeting?
When will Akouos present its findings?
What condition does AK-OTOF target?
What does AK-antiVEGF aim to treat?
What were the results of the AK-OTOF study?
